Corbus Pharmaceuticals (NASDAQ:CRBP) Receives "Buy" Rating from HC Wainwright

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $75.00 price target on the biopharmaceutical company's stock.

CRBP has been the subject of a number of other research reports. Piper Sandler started coverage on Corbus Pharmaceuticals in a research note on Monday, December 2nd. They issued an "overweight" rating and a $35.00 price objective for the company. Wedbush restated an "outperform" rating and issued a $51.00 price objective on shares of Corbus Pharmaceuticals in a research note on Monday, November 4th. Finally, StockNews.com upgraded Corbus Pharmaceuticals to a "sell" rating in a research note on Monday, January 13th. One analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $61.38.

Corbus Pharmaceuticals Stock Down 1.2 %

NASDAQ CRBP traded down $0.10 on Tuesday, reaching $8.18. The company had a trading volume of 186,020 shares, compared to its average volume of 254,577. The stock has a market capitalization of $99.63 million, a P/E ratio of -1.74 and a beta of 2.63. The company's fifty day moving average is $11.35 and its 200 day moving average is $24.36. Corbus Pharmaceuticals has a 52-week low of $7.64 and a 52-week high of $61.90.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC lifted its holdings in Corbus Pharmaceuticals by 215.0% during the 4th quarter. Millennium Management LLC now owns 386,653 shares of the biopharmaceutical company's stock worth $4,563,000 after purchasing an additional 263,902 shares in the last quarter. Orbimed Advisors LLC lifted its holdings in Corbus Pharmaceuticals by 28.5% during the 4th quarter. Orbimed Advisors LLC now owns 1,172,287 shares of the biopharmaceutical company's stock worth $13,833,000 after purchasing an additional 259,735 shares in the last quarter. Altium Capital Management LLC lifted its holdings in Corbus Pharmaceuticals by 97.4% during the 4th quarter. Altium Capital Management LLC now owns 385,000 shares of the biopharmaceutical company's stock worth $4,543,000 after purchasing an additional 190,000 shares in the last quarter. State Street Corp lifted its holdings in Corbus Pharmaceuticals by 34.6% during the 3rd quarter. State Street Corp now owns 595,576 shares of the biopharmaceutical company's stock worth $12,287,000 after purchasing an additional 153,243 shares in the last quarter. Finally, Prosight Management LP lifted its holdings in Corbus Pharmaceuticals by 107.7% during the 4th quarter. Prosight Management LP now owns 270,000 shares of the biopharmaceutical company's stock worth $3,186,000 after purchasing an additional 140,000 shares in the last quarter. Institutional investors own 64.64% of the company's stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.